Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Investors may find this activity noteworthy as it could indicate insider confidence in the company’s future performance. For further insights into NVO stock, check out TipRanks’ Stock Analysis page.

Meanwhile, semaglutide remains on the shortages list, but Novo Nordisk hopes it won’t be for long. The company last week ...

Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...